The Experiment Study Of The Targeting Imaging Of Bifunctional Optical And MRI Nano-probe FUSPIO@BSA-CD133mAb Against CD133-positive Glioma Stem Cells

Objective:To investigate the toxicity of the bifunctional optical and MRI nano-probefUSPIO@BSA-CD133mAb in vitro. To determine whether CD133-positive glioma stemcells（GSC） can be specifically and efficiently targeted by bifunctional optical and MRInano-probe, and whether GSC can be detected by MRI and optical imaging.methods:CD133monoclonal antibodies（Anti-CD133Antibody） and Fluorescentultrasmall superparamagnetism Fe₃O₄magnetic nanoparticles coated by Fetal bovineserum albumin （fUSPIO@BSA） were connected by carbodiimide to form bifunctionaloptical and MRI nano-probe fUSPIO@BSA-CD133mAb and then the exosyndromes ofthe oxide-iron nanocomposite were evaluated;to calibrate Fe concentration infUSPIO@BSA by ICP-AEC.MTT-based toxicity and proliferation assay was performed toanalyse the potential toxicity of fUSPIO@BSA-CD133mAb. Magnetic resonance imaging（MRI） signal strength variation was detected by3.0T MRI, afterfUSPIO@BSA-CD133mAb/fUSPIO@BSA with Fe concentration100μg/ml incubatingSU2-GSC for2hours. The optical imaging ability of fUSPIO@BSA-CD133mAb andSU2-GSC incubating for30min was evaluated by confocal laser scanning microscopy cy-5parameters.Result:The result of fUSPIO@BSA-CD133mAb exhibited excellent stability invarious physiological. The average diameter of the nanoparticles was8nm, and thehydration kinetics particle size of about25nm.ICP-AEC measured Fe concentration infUSPIO@BSA-CD133mAb for30.2mmol/L.The MTT assay showed thatfUSPIO@BSA-CD133mAb did not affect proliferation of SU2-GSC. The result of3.0TMRI showed the T2signal intensity of fUSPIO@BSA-CD133mAb group（91.6±4.278）was lower thanfUSPIO@BSA group （302.4±6.986） and control group （396.8±6.979）,three groups of SU2cells T2signal value difference was statistically significant （P<0.001）. fUSPIO@BSA-CD133mAb combined with targeted SU2-GSC walls exhibited a circularred fluorescence and fUSPIO@BSA internalized by SU2-GSC under confocal laserscanning microscope.Conclusion:â‘ fUSPIO@BSA-CD133mAb is innocuous and suitable for specific andefficient targeting SU2-GSC.â‘¡MRI and optical imaging in conjunction withfUSPIO@BSA-CD133mAb can distinguish CD133-positive GSC.â‘¢This research will benanometer technology and magnetic resonance imaging （MRI） technology and targeting,fluorescence and magnetic resonance imaging （MRI） of a double detection,complementary advantages, at the same time can take advantage of this probe couplingrelated stem cell of chemotherapy and radiotherapy sensitization drugs, to implement thedynamic evaluation of curative effect, for the future can be developed at the same time hastargeted diagnosis and molecular targeted therapy of probe to lay the theoretical foundationand work.